Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 6/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096800 | 0.93 | CYP11B2 (0.65) | CYP11B2ALDH1A1KDM4EIDO1 | |
| SCHEMBL1097775 | 0.84 | CYP11B2 (0.66) | CYP11B2ALDH1A1KDM4EHTTIDO1 | |
| SCHEMBL1096649 | 0.83 | CYP11B2 (0.60) | CYP11B2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1099240 | 0.80 | CYP11B2 (0.66) | CYP11B2ALDH1A1SMN1; SMN2RAB9AIDO1 | |
| SCHEMBL1097382 | 0.79 | CYP11B2 (0.73) | CYP11B2ALDH1A1IDO1 | |
| SCHEMBL1099042 | 0.79 | CYP11B2 (0.73) | CYP11B2IDO1 | |
| SCHEMBL1098831 | 0.78 | CYP11B2 (0.79) | CYP11B2ALDH1A1KDM4EIDO1 | |
| SCHEMBL1098830 | 0.78 | CYP11B2 (0.79) | CYP11B2ALDH1A1KDM4EIDO1 | |
| SCHEMBL1096266 | 0.76 | CYP11B2 (0.69) | CYP11B2IDO1 | |
| SCHEMBL1096267 | 0.76 | CYP11B2 (0.69) | CYP11B2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | CYP11B2 28/4885ALDH1A1 215/4885SMN1; SMN2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.